Abbott to Close Exact Sciences Acquisition, Adding $3 Billion Sales and 0.5% Growth
Abbott will close the acquisition of Exact Sciences on March 23, 2026 after securing all regulatory clearances necessary for the transaction. The deal is expected to add approximately $3 billion in incremental sales for 2026, accelerate revenue growth by 0.5% and dilute adjusted EPS by about $0.20.
1. Acquisition Closing
Abbott has secured all required regulatory approvals and will finalize its acquisition of Exact Sciences on March 23, 2026, marking its official entry into the cancer screening and diagnostics market.
2. Financial Impact
The transaction is projected to contribute roughly $3 billion in additional sales during 2026, boost Abbott's overall sales growth by 0.5%, and dilute adjusted earnings per share by approximately $0.20.
3. Strategic Fit
By integrating Exact Sciences, Abbott gains leadership in the fast-growing $60 billion U.S. cancer screening and precision oncology diagnostics segments, aligning with its strategy to expand preventative and personalized healthcare offerings.
4. Product Portfolio
Exact Sciences brings market-leading tests including Cologuard for colorectal screening, Oncotype DX for breast cancer treatment decisions, Oncodetect for MRD monitoring, and the next-generation Cancerguard multi-cancer detection assay.